Human M-CSF, His Tag (Cat. No. MCF-H5247) captured on CM5 Chip via anti-His antibody can bind Human M-CSF R, Fc Tag, low endotoxin (Cat. No. CSR-H5258) with an affinity constant of 1.9 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mirimostim | P-100; CSF-HU | Approved | Jcr Pharmaceuticals | Costilate, Leukoprol | Japan | Neutropenia | Jcr Pharmaceuticals Co Ltd | 1991-01-01 | Neutropenia | Details |
Surufatinib | HMPL-012 | Approved | Hutchison Medipharma Ltd | 苏泰达, SULANDA | Mainland China | Neuroendocrine Tumors | Hutchison Huangpu Medicine (Shanghai) Co Ltd | 2020-12-29 | Solid tumours; Hematologic Neoplasms; Biliary Tract Neoplasms; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Bile Duct Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Hodgkin Disease; Arthritis, Rheumatoid; Glioblastoma; Giant Cell Tumors; Prostatic Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute | Details |
Pazopanib Hydrochloride | GW-786034; SB-786034; GSK-786034; GW-786034B | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Patorma, Votrient | Mainland China | Carcinoma, Renal Cell | Novartis Pharma Schweiz Ag | 2009-10-19 | Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer Ag | Resihance, Stivarga | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD | Approved | Pfizer Pharmaceuticals Ltd (China) | Sutent, 索坦 | Japan | Pancreatic neuroendocrine tumors (pNET) | Pfizer Inc | 2006-01-26 | Breast Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Diabetic macular oedema; Prostatic Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Stomach Neoplasms; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Edicotinib | JNJ-244; JNJ-527; PRV-6527; JNJ-40346527 | Phase 2 Clinical | Johnson & Johnson | Arthritis, Rheumatoid; Hodgkin Disease; Leukemia, Myeloid, Acute; Crohn Disease | Details |
C-019199 | C019199 | Phase 1 Clinical | Fujian Haixi New Pharmaceutical Co Ltd | Solid tumours | Details |
Emactuzumab | RG-7155; 6FY6EI1X8R; RO-5509554 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Lymphoma, Non-Hodgkin | Details |
SOMCL-15-290 | SOMCL-15-290 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Squamous Cell | Details |
AMB-05X | AMB-05X | Phase 2 Clinical | Amgen Inc | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular; Testicular Neoplasms | Details |
BLZ-945 | BLZ-945 | Phase 2 Clinical | Novartis Pharma Ag, Celgene Corp | Solid tumours; Amyotrophic Lateral Sclerosis | Details |
Cilmostim | CSF-1 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Hypercholesterolemia; Presbyopia | Details |
Vimseltinib | DCC-3014 | Phase 3 Clinical | Deciphera | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular | Details |
LY-3022855 | IMC-CS4; LY-3022855 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Neoplasm Metastasis; Melanoma | Details |
PMI-04 | Phase 1 Clinical | Precision Molecular | Nerve Degeneration | Details | |
BC-006 monoclonal antibody | BC-006; BC006 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
Cabiralizumab | FPA-008; ONO-4687; BMS-986227 | Phase 2 Clinical | Five Prime Therapeutics | Giant Cell Tumor of Tendon Sheath; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Synovitis, Pigmented Villonodular; Carcinoma, Renal Cell; Arthritis, Rheumatoid; Pancreatic Neoplasms; Glioma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
TT-00420 | TT-00420 | Phase 2 Clinical | Yaojie Ankang (Nanjing) Technology Co Ltd | Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Gallbladder Neoplasms; Thyroid Neoplasms | Details |
Derazantinib | ARQ-087; BAL-087; ARQ-087.2HCl; AQ-14741087 | Phase 2 Clinical | Arqule | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
Elzovantinib | TPX-0022 | Phase 1 Clinical | Turning Point Therapeutics Inc | Solid tumours | Details |
EI-1071 | EI-1071 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Giant Cell Tumor of Tendon Sheath; Alzheimer Disease | Details |
TT-00420/Atezolizumab | Phase 1 Clinical | Yaojie Ankang (Nanjing) Technology Co Ltd | Gastrointestinal Neoplasms | Details | |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
ABSK-021 | ABSK-021 | Phase 1 Clinical | Abbisko Therapeutics | Solid tumours; Giant Cell Tumor of Tendon Sheath; Pancreatic Neoplasms; Graft vs Host Disease; Triple Negative Breast Neoplasms; Sarcoma; Lung Neoplasms; Amyotrophic Lateral Sclerosis | Details |
Q-702 | Q-702 | Phase 1 Clinical | Qurient Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
HMPL-653 | HMPL-653 | Phase 1 Clinical | Hutchison Huangpu Medicine (Shanghai) Co Ltd | Solid tumours; Giant Cell Tumor of Tendon Sheath | Details |
Axatilimab | SNDX-6352; UCB-6352 | Phase 2 Clinical | Ucb, Incyte Corp | Cytokine Release Syndrome; Solid tumours; Graft vs Host Disease; Respiratory Distress Syndrome, Adult; Coronavirus Infections; Neoplasm Metastasis | Details |
APL-102 | APL-102; CBT-102 | Phase 1 Clinical | Apollomics | Solid tumours | Details |
Recombinant human GM-CSF oncolytic herpes simplex virus type 2 (OH2) | BS-001; OH-2 | Phase 2 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Lung Neoplasms; Melanoma | Details |
This web search service is supported by Google Inc.